Citius Oncology, Inc.CTOR
Price (close)
$1.05
Market cap
$97.6M
P/E
—
Revenue (TTM)
—
Net income
-$46.1M
Dividend yield
—
1-year total return
-42.3%
Net margin
—
Revenue growth
—
Debt / equity
0.16x
What Citius Oncology, Inc. does.
is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. The Company’s strategy
centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and competitive
advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net income | — | — | -$12.7M | -$21.1M | -$24.8M |
More on CTOR.
- Citius Oncology, Inc. summary
- Citius Oncology, Inc. financial statements
- Citius Oncology, Inc. key metrics
- Citius Oncology, Inc. health scores and style box
- Citius Oncology, Inc. earnings
- Citius Oncology, Inc. dividends
- Citius Oncology, Inc. valuation
- Citius Oncology, Inc. ownership and insiders
- Citius Oncology, Inc. peers
Figures from Citius Oncology, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.